Médecine

Paramédical

Autres domaines


Suscribirse

Clinical efficacy of glucocorticoid on the treatment of patients with COVID-19 pneumonia: A single-center experience - 27/10/20

Doi : 10.1016/j.biopha.2020.110529 
Yan Hu 1, Tingping Wang 1, Zhimin Hu, Xuan Wang, Zhengbin Zhang, Li Li , 1 , Peng Peng , 1
 Wuhan Pulmonary Hospital, Wuhan Institute for Tuberculosis Control, Wuhan 430030, Hubei, China 

Corresponding authors at: Wuhan Pulmonary Hospital, Wuhan Tuberculosis Control institute, Wuhan 430030, Hubei, China.Wuhan Pulmonary HospitalWuhan Tuberculosis Control instituteWuhanHubei430030China

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Graphical abstract

The clinical efficacy of glucocorticoid therapy on the treatment of patients with Coronavirus Disease 2019 (COVID-19) pneumonia was investigated. This retrospective study showed glucocorticoid therapy did not significantly influence the clinical course of COVID-19 pneumonia, including imaging progress and the time duration for negative transformation of nucleic acid, and glucocorticoid therapy did not significantly influence the outcomes nor the adverse events of COVID-19 pneumonia.




El texto completo de este artículo está disponible en PDF.

Highlights

Glucocorticoid therapy did not significantly influence the clinical course of Coronavirus Disease 2019 (COVID-19) pneumonia, including imaging progress and the time duration for negative transformation of nucleic acid.
Glucocorticoid therapy did not significantly influence the adverse events of COVID-19 pneumonia.
Glucocorticoid therapy did not significantly influence the outcomes of COVID-19 pneumonia.

El texto completo de este artículo está disponible en PDF.

Abstract

The aim of the present study was to identify the clinical efficacy of glucocorticoid therapy on the treatment of patients with Coronavirus Disease 2019 (COVID-19) pneumonia. Clinical and laboratory parameters were collected from 308 patients with COVID-19 pneumonia from the fever clinic of Wuhan Pulmonary Hospital (Wuhan City, Hubei Province, China) between January 14, 2020 and February 9, 2020, of which 216 patients received low-dose (equivalent of methylprednisolone 0.75–1.5 mg/kg/d) glucocorticoid treatment. The effect of glucocorticoid on imaging progress, adverse events, nucleic acid results and the outcomes were investigated. Lymphocyte count and C-reactive protein (CRP) significantly differed between the glucocorticoid therapy and non-glucocorticoid therapy groups. Compared with the non-glucocorticoid therapy group, glucocorticoid therapy did not significantly influence the clinical course of COVID-19 pneumonia, including imaging progress and the time duration for negative transformation of nucleic acid. Glucocorticoid therapy did not significantly influence the outcomes nor the adverse events of COVID-19 pneumonia. For the treatment of COVID-19 pneumonia, systemic and in-depth investigation is needed to determine the timing and dosage of glucocorticoids needed to inhibit overwhelming inflammatory response and not the protective immune response to COVID-19 pneumonia.

El texto completo de este artículo está disponible en PDF.

Keywords : COVID-19, Glucocorticoid therapy, Clinical course


Esquema


© 2020  Publicado por Elsevier Masson SAS.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 130

Artículo 110529- octobre 2020 Regresar al número
Artículo precedente Artículo precedente
  • Effects of total saponins from Panacis majoris Rhizoma and its degradation products on myocardial ischemia-reperfusion injury in rats
  • Min Li, Xuwen Li, Limei Zhou, Yongri Jin
| Artículo siguiente Artículo siguiente
  • Possible mechanisms for the renoprotective effects of date palm fruits and seeds extracts against renal ischemia/reperfusion injury in rats
  • Mansour A. Alghamdi, Abdelaziz M. Hussein, Laith N. AL-Eitan, Eman Elnashar, Ahmed Elgendy, Asim M. Abdalla, Seham Ahmed, Wael A. Khalil

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.